Comparing Sublingual and Inhaled Cannabis Therapies for Low Back Pain: An Observational Open-Label Study DOI Creative Commons
Dror Robinson, Sivan Ritter,

Mustafa Yassin

et al.

Rambam Maimonides Medical Journal, Journal Year: 2022, Volume and Issue: 13(4), P. e0026 - e0026

Published: Oct. 27, 2022

Medical cannabis is becoming an acceptable treatment modality in medicine, especially for pain relief. Concurrently, use more prevalent worldwide, a public demand-driven trend despite the lack of established scientific basis. This observational open-label study sought to investigate effectiveness therapy alleviating low back symptoms.Two types modalities were sequentially administered chronic patients. After initial 1-month washout period (WO1), first was cannabidiol (CBD)-rich sublingual extract 10 months. Following another period, second modality, Δ9-tetrahydrocannabinol (THC)-rich smoked inflorescence (whole dried flowers) 12 months.Enrolled 24 patients whose advanced imaging studies (i.e. computerized tomography or magnetic resonance lumbar spine) revealed disc herniation spinal stenosis. Three dropped out but resumed participation receive THC-rich smoking therapy. minimum 2 years, had reduced lower symptoms, as assessed by Oswestry Disability Index, SF-12 patient-reported outcome questionnaire, and visual analogue scale. Pain reduction not significant during part study; however, inhaled study.Our findings indicate that effective than CBD-rich treating safe pain.

Language: Английский

Parallel evolution of cannabinoid biosynthesis DOI
Paula Berman, Luis Alejandro de Haro, Adam Jóźwiak

et al.

Nature Plants, Journal Year: 2023, Volume and Issue: 9(5), P. 817 - 831

Published: May 1, 2023

Language: Английский

Citations

37
Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults DOI Creative Commons
Adrianne R. Wilson‐Poe, Tristin Smith, Michael R. Elliott

et al.

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(12), P. e2347373 - e2347373

Published: Dec. 13, 2023

This survey study characterizes past-year use prevalence and factors associated with of cannabidiol, cannabigerol, cannabinol, Δ8-tetrahydrocannabinol among US adults.

Language: Английский

Citations

19
Opportunities, Challenges, and Scientific Progress in Hemp Crops DOI Creative Commons
Kacper Piotr Kaminski, Julia Hoeng,

Fernando Goffman

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(10), P. 2397 - 2397

Published: May 20, 2024

The resurgence of cannabis (Cannabis sativa L.) has been propelled by changes in the legal framework governing its cultivation and use, increased demand for hemp-derived products, studies recognizing industrial health benefits hemp. This led to creation novel high-cannabidiol, low-Δ9-tetrahydrocannabinol varieties, enabling hemp crop expansion worldwide. review elucidates recent implications Europe, with a focus on legislative impacts practices, prospective breeding efforts, dynamic scientific landscape surrounding this crop. We also current cultivars’ cannabinoid composition European market major differences that United States.

Language: Английский

Citations

7
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial DOI Creative Commons
Carrie Cuttler, Amanda Stueber, Ziva D. Cooper

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: July 13, 2024

Abstract Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. However, there are no published clinical trials to corroborate these findings humans. The primary objective of this study was examine acute effects CBG on anxiety, stress, mood. Secondary objectives were whether produces subjective drug or motor cognitive impairments. A double-blind, placebo-controlled cross-over field trial conducted 34 healthy adult participants. Participants completed two sessions (with one-week washout period) via Zoom. In each, they provided ratings mood, prior double-blind administration 20 mg hemp-derived placebo tincture (T0). These collected again after participants ingested the product an online survey (T1), Trier Social Stress Test (T2), verbal memory test DRUID impairment app (T3). Relative placebo, significant main effect overall reductions anxiety as well stress at T1. also enhanced relative placebo. There evidence impairment. may represent novel option reduce adults.

Language: Английский

Citations

6
Cannabigerol: a bibliometric overview and review of research on an important phytocannabinoid DOI
Chinedu P. Anokwuru,

Felix L. Makolo,

Maxleene Sandasi

et al.

Phytochemistry Reviews, Journal Year: 2022, Volume and Issue: 21(5), P. 1523 - 1547

Published: Jan. 24, 2022

Language: Английский

Citations

24
Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain DOI Creative Commons
Rahul Nachnani,

Diana E. Sepúlveda,

Jennifer L. Booth

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(10), P. 1442 - 1442

Published: Oct. 11, 2023

Cannabigerol (CBG), derived from the cannabis plant, acts as an acute analgesic in a model of cisplatin-induced peripheral neuropathy (CIPN) mice. There are no curative, long-lasting treatments for CIPN available to humans. We investigated ability chronic CBG alleviate mechanical hypersensitivity due mice by measuring responses 7 and 14 days daily CBG. found that treatment (i.p.) consecutive significantly reduced male female with pain sensitivity up 60–70% baseline levels (p < 0.001 all), 24 h after last injection. Additionally, we did not evoke tolerance incur significant weight change or adverse events. The efficacy was independent estrous cycle phase. Therefore, administration can provide at least antinociceptive effect These findings support study neuropathic therapy, which without both males females.

Language: Английский

Citations

14
Single and Combined Effects of Cannabigerol (CBG) and Cannabidiol (CBD) in Mouse Models of Oxaliplatin-Associated Mechanical Sensitivity, Opioid Antinociception, and Naloxone-Precipitated Opioid Withdrawal DOI Creative Commons

Sean A. Hayduk,

Amanda C. Hughes,

Rachel L. Winter

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(6), P. 1145 - 1145

Published: May 22, 2024

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent and dose-limiting complications in chemotherapy patients, with estimates at least 30% patients experiencing persistent for months or years after treatment cessation. An emerging potential intervention CIPN cannabinoid-based pharmacotherapies. We have previously demonstrated that psychoactive CB1/CB2 cannabinoid receptor agonist Δ9-tetrahydrocannabinol (Δ9-THC) non-psychoactive, minor phytocannabinoid cannabidiol (CBD) can attenuate paclitaxel-induced mechanical sensitivity a mouse model CIPN. then showed two compounds acted synergically when co-administered model, giving credence to so-called entourage effect. others also CBD several opioid-associated behaviors. Most recently, it was reported another cannabinoid, cannabigerol (CBG), attenuated cisplatin-associated mice. Therefore, goals present set experiments were determine single combined effects (CBG) oxaliplatin-associated sensitivity, naloxone-precipitated morphine withdrawal, acute antinociception male C57BL/6 Results CBG reversed only under select dosing conditions, interactive sub-additive synergistic depending upon conditions too. Pretreatment selective α2-adrenergic, CB1, CB2 antagonist significantly effect CBG. decreased jumping behavior alone synergistically combination, while antinociceptive CBD. Taken together, may therapeutic like as rodent models, its opioids other phytocannabinoids should continue be characterized.

Language: Английский

Citations

6
Cannabinoid CB1 receptors regulate salivation DOI Creative Commons

Kelsey Andreis,

Jenna Billingsley,

Kian Naimi Shirazi

et al.

Scientific Reports, Journal Year: 2022, Volume and Issue: 12(1)

Published: Aug. 19, 2022

Saliva serves multiple important functions within the body that we typically take for granted, such as helping prepare food swallowing and defense against oral pathogens. Dry mouth is a primary symptom of Sjӧgren's syndrome side effect many drug treatments. Cannabis users frequently report dry mouth, but basis this still unknown. If effects occur via endogenous cannabinoid signaling system, then may represent novel mechanism regulation salivation. We examined expression CB1 receptors in submandibular salivary gland using immunohistochemistry tested salivation by THC cannabinoid-related ligands. now are expressed axons cholinergic neurons innervating gland. No staining seen epithelial cells (acinar ductal), or myoepithelial (MECs). Treatment with (4 mg/kg, IP) receptor agonist CP55940 (0.5 mg/kg) reduced both male female mice 1 h after treatment. CBD had no on its own reversed concentration-dependent manner. Neither antagonist SR141716 nor CB2-selective JWH133 an also found fatty acid amide hydrolase (FAAH), enzyme metabolizes endocannabinoid anandamide related lipids, regulates Salivation was FAAH knockout well treated blocker URB597 mg/kg). mice. protein detected intracellularly acinar not ductal cells. In lipidomics experiments, chiefly elevated levels acylethanolamines, including anandamide, acyglycines. Our results consistent model wherein endocannabinoids activate likely acts plugging into activating to reduce salivation, thus offering underlying reported cannabis users.

Language: Английский

Citations

22
Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts DOI Creative Commons
Gérard Mick,

Pascal Douek

Pain and Therapy, Journal Year: 2024, Volume and Issue: 13(5), P. 1063 - 1094

Published: Aug. 3, 2024

Interest in medical cannabis and cannabis-based medicinal products (CBMPs) has increased greatly recent years. Two cannabinoids are of principal importance; delta-9-tetrahydrocannabinol (∆9-THC), the primary psychoactive component, also cannabidiol (CBD), considered non-intoxicating. Each distinct mechanisms action different therapeutic potentials. CBMPs differ their ∆9-THC CBD components; predominantly ∆9-THC, balanced formulations with equivalent elements, CBD-predominant products. In this narrative review, we evaluate published evidence for clinical benefits overall well-being. We review safety profile discuss potential dependence CBMPs. Evidence can be drawn from a wide range randomized other controlled studies observational real-world studies. Most data registry supportive ∆9-THC-based (∆9-THC-predominant or CBMPs) management chronic neuropathic pain. Balanced effective reducing spasticity multiple sclerosis. show benefit providing symptomatic anxiety, nausea, improving sleep, but place specific is more subtle, choice guided by circumstances. Symptomatic improvements accompanied improved quality life Safety indicate that generally well tolerated most patients without contraindications. The majority adverse effects non-serious, transient; principally associated dose-dependent. contrast to recreational use, there little have any dependence.

Language: Английский

Citations

4
Amyotrophic Lateral Sclerosis, the Endocannabinoid System, and Exogenous Cannabinoids: Current State and Clinical Implications DOI Open Access
Travis T. Denton, Gregory T. Carter,

Moses Goddard

et al.

Muscle & Nerve, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

ABSTRACT A unifying mechanistic cause for amyotrophic lateral sclerosis (ALS) remains uncertain. Multiple pathophysiological processes appear to occur simultaneously. Cannabinoids, including delta‐9‐tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), and others found in cannabis, cannabis extracts (CEs), have activity these pathogenic pathways, which led increasing interest cannabinoids as therapeutic agents ALS. The use of a treatment strategy is substantiated by preclinical evidence suggesting role the endocannabinoid system (ECS) ALS other neurodegenerative disorders. Preclinical data indicate that CEs powerful antioxidative, anti‐inflammatory, neuroprotective effects SOD1 G93A mouse model murine models has been shown prolong neuronal cell survival, leads delayed onset disease state, slows progression disease. Although research humans limited, few studies suggest CBD, humans, provide benefits both motor symptoms, rigidity, cramps, fasciculations, non‐motor symptoms sleep quality, pain, emotional quality life, depression. There need further, well‐designed clinical trials validate further an individual cannabinoid, or combination cannabinoids, disease‐modifying therapy

Language: Английский

Citations

0